Inventors list

Assignees list

Classification tree browser

Top 100 Inventors

Top 100 Assignees


9,10-seco- cyclopentanohydrophenanthrene ring system (e.g., vitamin D, etc.) DOAI

Subclass of:

514 - Drug, bio-affecting and body treating compositions

514001000 - DESIGNATED ORGANIC ACTIVE INGREDIENT CONTAINING (DOAI)

Patent class list (only not empty are listed)

Deeper subclasses:

Class / Patent application numberDescriptionNumber of patent applications / Date published
514168000 With a vitamin type active ingredient 17
Entries
DocumentTitleDate
20120184514VITAMIN D COMPOUNDS AND METHODS FOR PREPARING SAME - An air-stable, high-melt 1a-hydroxy-vitamin D3 compound, methods for preparing an animal feed composition, methods of preparing 1α-hydroxy-vitamin D3, methods of enhancing phytate phosphorus and calcium utilization, and an animal feed regime are provided.07-19-2012
20100009949NOVEL METHOD - The invention provides for the use of Vitamin D compounds such as 1-alpha-fluoro-25-hydroxy-16,23E-diene-26,27-bishomo-20-epi-chole-calciferol, in the prevention or treatment of prostate cancer.01-14-2010
20100152143Methods of Treating Skin Disorders with Caffeic Acid Analogs - Embodiments of the invention generally relate to pharmaceutical compositions containing at least one caffeic acid compound and methods for the topical treatment of proliferative and inflammatory skin disorders such as plaque psoriasis, atopic dermatitis, and other disorders. In some embodiments, the topical treatment includes applications of the pharmaceutical composition containing at least one caffeic acid compound or a mixture of caffeic acid compounds such as caffeic acid ester compounds, caffeic acid amide compounds, analogues thereof, derivatives thereof, salts thereof, or mixtures thereof. The pharmaceutical composition or topical dosage may contain the caffeic acid compound at a concentration by weight within a range from about 0.01% to about 20%, preferably, from about 0.1% to about 15%, preferably, from about 1% to about 10%, more preferably, from about 3% to about 7%, and more preferably, from about 4% to about 6%.06-17-2010
20110195941Methods of Use To Orally and Topically Treat Acne and Other Skin Conditions By Administering a 19-NOR Containing Vitamin D Analog With or Without a Retinoid - Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-methylene-1α,25-dihydroxyvitamin D08-11-2011
20130085121PHARMACEUTICAL COMPOSITIONS COMPRISING PHOSPHATE BINDER, CALCIUM RECEPTOR-ACTIVE COMPOUND AND/OR ACTIVE VITAMIN D - The present invention is an oral solid pharmaceutical compositions for the treatment of kidney diseases and mineral bone disorder including a phosphate binder, a calcium receptor-active compound and at least one pharmaceutically acceptable excipient, the invention further including a method for preparing the pharmaceutical compositions including the steps of granulating cinacalcet and/or sevelamer and/or vitamin D by one of a wet and a dry granulation process, each with at least one pharmaceutically acceptable excipient to form cinacalcet granules and/or sevelamer granules and/or vitamin D granules, mixing at least two of the cinacalcet granules, sevelamer granules and vitamin D granules to form a granules mixture and compressing the granules mixture to tablets or encapsulating the granules mixture into capsules or pulverizing the granules mixture into a dispersion powder.04-04-2013
20100075933INJECTABLE COMPOSITIONS OF VITAMIN D COMPOUNDS - Pharmaceutical injectable compositions comprising at least one vitamin D compound as an active agent, processes for preparing such compositions, and methods of using such compositions.03-25-2010
20100041631METHODS AND AGENTS FOR TREATING TUBERCULOSIS - The present invention relates to the treatment of tuberculosis (mycobacterial infections) by the use of KshAB complex inhibitors, or a KstD molecule, or a HsaAB complex, or a HsaC molecule, or a HsaD molecule. The application also includes a method for identifying an inhibitor or modulator of the previously mentioned molecules and complexes.02-18-2010
20080312198PHARMACEUTICAL PRODUCTS CONTAINING HORMONES AND A 25-HYDROXY VITAMIN D COMPOUND - The present invention relates to pharmaceutical products containing progestins in combination with the 25 hydroxy Vitamin D compounds. The 25 hydroxy Vitamin D compounds are preferably administered with the progestins. In OC and HRT regimens, the 25 hydroxy Vitamin D compounds can be administered daily, or on a non-daily basis, and if so, preferably when the progestin dosages are the highest in the cycle.12-18-2008
20120165300DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1ALPHA,25-DIHYDROXYVITAMIN D3 - Compounds of formula I are provided where X06-28-2012
20100069339NOVEL METHOD OF TREATMENT OF MALE SUB-FERTILITY - There is provided a method of treatment of male sub-fertility by using a vitamin D compound. Compositions and uses are also provided.03-18-2010
2009009914020-Alkyl, Gemini Vitamin D3 Compounds and Methods of Use Thereof - The invention provides 20-alkyl Gemini vitamin D04-16-2009
201000099432-Methylene-(22E)-25-(1-Methylene-Hexyl)-26,27-Cyclo-22-Dehydro-19-Nor-Vit- amin D Analogs - This invention discloses 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(22E)-25-(1-methylene-hexyl)-26,27-cyclo-22-dehydro-19-nor-1α,24(R)-dihydroxyvitamin D01-14-2010
20090093445RELEASE REAGENT FOR VITAMIN D COMPOUNDS - The present invention concerns a reagent composition for releasing vitamin D compounds bound to vitamin D-binding protein, a method for the detection of a 25-hydroxyvitamin D compound in which the 25-hydroxyvitamin D compound is released from vitamin D-binding protein using this reagent and the mixture obtained in this manner is analyzed, the use of the reagent to release vitamin D compounds as well as a kit for detecting 25-hydroxyvitamin D which contains the reagent for releasing vitamin D compounds in addition to the usual immunological reagents.04-09-2009
20130059825Antibodies to 25-HYDROXY Vitamin D2 and D3 and Uses Thereof - Provided herein are antigenic molecules that can be used to generate antibodies capable of binding to a vitamin D derivative, such as 25-hydroxyvitamin D2 and/or 25-hydroxyvitamin D3, or a 25-hydroxyvitamin D analog, such as a vitamin D-C22 immunogenic molecule or compound. Antibodies produced using these antigenic molecules, and related antigenic compounds, are also described. In addition, disclosed herein are methods for detecting vitamin D deficiency in a subject, methods for treating a subject suspected of having a vitamin D deficiency, methods for monitoring progression of vitamin D deficiency in a subject, and methods for monitoring treatment of vitamin D deficiency in a subject in need thereof. Also provided are methods and reagents for the detection or quantification of 25-hydroxyvitamin D2 and D3, methods for stabilizing vitamin D analogs, and methods for separating 25-hydroxyvitamin D2 and D3 from vitamin D binding protein in a biological sample.03-07-2013
20130065867Compositions and methods for using same for treating posterior blepharitis - This invention relates to methods for administering an effective amount of a dietary or nutritional supplement composition that effectively changes the quality of the meibum lipid composition of inflamed or dysfunctional meibomian glands so as to improve or increase tear break up time, reduce tear osmolarity, and elevate the omega-3 index, while reducing or eliminating the symptoms associated with dry eye or meibomianitis. The dietary or nutritional supplement composition administered to the patient suffering from inflamed or dysfunctional meibomian glands comprises an effective amount of omega-3 fatty acids.03-14-2013
20090221537USE OF 25-HYDROXY VITAMIN D3 TO IMPROVE VITALITY OF ANIMALS - The present invention relates to the use of 25-hydroxy-vitamin D09-03-2009
20100087404METHOD OF TREATING AND PREVENTING HYPERPARATHYROIDISM WITH ACTIVE VITAMIN D ANALOGS - This invention relates to a method for treating or preventing hyperthyroidism secondary to chronic kidney disease by administering a sufficient amount of an active vitamin D analog utilizing a variety of effective treatment protocols.04-08-2010
20100087405FOOD SUPPLEMENTATION COMPOSITION CONTAINING ONE OR MORE VITAMIN D3 COMPOUNDS AND ONE OR MORE MAGNESIUM SALTS - Use of one or more vitamin D04-08-2010
20080293681SPRAYABLE PHARMACEUTICAL COMPOSITIONS COMPRISING A VITAMIN D DERIVATIVE AND AN OILY PHASE - Anhydrous sprayable physically and chemically stable pharmaceutical/dermatological compositions containing a vitamin D derivative as an active pharmaceutical ingredient, particularly calcitriol, and an oily phase are formulated into a physiologically-acceptable medium, and are useful for the treatment of a variety of conditions and afflictions, notably psoriasis.11-27-2008
20100022485FORMULATIONS COMPRISING A VITAMIN AND THE USE THEREOF TO MAKE FORTIFIED FEED AND PERSONAL CARE FORMULATIONS - The invention relates to aqueous formulations comprising alkoxylated castor oils with 15-25 ethyleneoxy units and a vitamin, preferably a fat-soluble vitamin, as well as to the use of such formulations in the process to administer the vitamin to an animal, or to make personal care formulations comprising the vitamin.01-28-2010
20080280859GEMINI VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF - The invention provides Gemini vitamin D11-13-2008
20110294765Procedure for obtaining an aqueous dispersion of alcohols and acids from jojoba oil, processes for obtaining self-emulsified jojoba oil, aqueous dispersions and emulsions of jojoba oil in the same and pharmaceutical or cosmetic compositions comprising the same - Processes for obtaining aqueous dispersions comprising alcohols and acids obtained by hydrolysis of jojoba oil. Hydrolyzed jojoba oil products are treated by a process comprising neutralization of jojoba fatty acids with aliphatic organic amines dissolved in a co-solvent followed by the dispersion of both the neutralized fatty acids together with jojoba alcohols in an aqueous medium. The products obtained, generically named hydrolyzed jojoba oil (HJO), promote transdermal absorption and are useful vehicles for carrying a wide range of pharmaceutical and cosmetic compositions, including pharmaceutical and cosmetic compositions comprising either lipophilic or hydrophilic active principles. The HJO can also be used to produce a semisolid, self-emulsified jojoba oil (SEJO), obtained by emulsifying the HJO in jojoba oil.12-01-2011
20090118244BENZODIAZEPINONE COMPOUNDS USEFUL IN THE TREATMENT OF SKIN CONDITIONS - The present invention provides a family of benzodiazepinone compounds and pharmaceutical compositions thereof. The present invention also provides methods of treating certain skin conditions, e.g., atopic dermatitis, rosacea, or psoriasis, by administering a benzodiazepinone and methods of reducing the proliferation of keratinocyte cells by exposing such cells to a benzodiazepinone.05-07-2009
201102947642-METHYLENE-19,26-NOR-(20S)-1alpha-HYDROXYVITAMIN D3 - Compounds of formula I are provided where X12-01-2011
20110269725NOVEL ESTROGENIC COMPOUNDS - Novel estrogenic compounds of Formula I are provided.11-03-2011
20090298799Methods of Treating Osteoporosis and Secondary Hyperparathyroidism Using 20-Methyl, Gemini Vitamin D3 Compounds - The invention provides for methods of using 20-methyl Gemini vitamin D12-03-2009
20100081637Eczema treatment with vitamin D and analogs thereof method, composition and cream - An eczema treatment method comprises application of a therapeutically effective composition in the form of an aqueous topical cream to an affected area of an exterior skin region of a patient, the aqueous topical cream comprising water, a water-soluble organic liquid, a surface active agent, and vitamin D04-01-2010
20120108554PROCESS FOR PREPARING HIGH PURITY 1alpha-HYDROXY VITAMIN D2 - The present invention relates to a process for purifying Doxercalciferol, a synthetic vitamin D analog, also known as 1α-hydroxy vitamin D05-03-2012
20090258845Combination Dosage Forms and Therapies for Supporting Bone Health - Combined therapies and oral dosage forms based on genistein for the support of osteoporotic health.10-15-2009
200901708222-Methylene-20-Methyl-19,24,25,26,27-Pentanor-Vitamin D Analogs - This invention discloses 2-methylene-20-methyl-19,24,25,26,27-pentanor-vitamin D analogs, and specifically 2-methylene-20-methyl-1α-hydroxy-19,24,25,26,27-pentanor-vitamin D07-02-2009
20090275540Pre-Compacted Calcium-Containing Compositions - A pre-compacted materiel comprising one or more calcium-containing compounds and one or more sugar alcohols, wherein the calcium-containing compound having a polycrystallic porous structure. The pre-compacted material is preferably obtained by roller compaction and is suitable for use in the further processing of the pre-compacted material into composition like e.g. tablets.11-05-2009
20100222307VITAMIN D AND VITAMIN D ANALOGS OR DERIVATIVES AS NEW ANTI-HYPERTENSIVE AGENTS - Methods and compositions to suppress renin expression and blood pressure in mammals are disclosed. Vitamin D and its analogues and derivatives, including Gemini compounds, are negative regulators of renin synthesis and blood pressure. Renin expression and plasma angiotensin II production were increased several fold in vitamin D receptor (VDR) null mice, leading to hypertension, cardiac hypertrophy and increased water intake. Vitamin D or its analogue-mediated regulation of renin expression and blood pressure is independent of calcium metabolism. Vitamin D analogues or derivatives are novel preventive or therapeutic anti-hypertension agents. Assays to identify novel vitamin D analogues or derivatives as anti-hypertensive agents are disclosed.09-02-2010
20090170819(20R)-23,23-Difluoro-2-Methylene-19-Nor-Bishomopregnacalciferol-Vitamin D Analogs - This invention discloses (20R)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs, and specifically (20R)-23,23-difluoro-1 α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.07-02-2009
20090170818(20S)-23,23-Difluoro-Methylene-19-Nor-Bishomopregnacalciferol-Vitamin D Analogs - This invention discloses (20S)-23,23-difluoro-2-methylene-19-nor-bishomopregnacalciferol-vitamin D analogs, and specifically (20S)-23,23-difluoro-1α-hydroxy-2-methylene-19-nor-bishomopregnacalciferol, and pharmaceutical uses therefor. This compound exhibits pronounced activity in arresting the proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agent and for the treatment of skin diseases such as psoriasis as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion. This compound also has little, if any, calcemic activity and therefore may be used to treat autoimmune disorders or inflammatory diseases in humans as well as renal osteodystrophy. This compound may also be used for the treatment or prevention of obesity.07-02-2009
200901708202-Methylene-(20S,25R)-19,26-Dinor-Vitamin D Analogs - This invention discloses 2-methylene-(20S,25R)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25R)-19,26-dinor-1α,25-dihydroxyvitamin D07-02-2009
200901708212-Methylene-(20S,25S)-19,26-Dinor-Vitamin D Analogs - This invention discloses 2-methylene-(20S,25S)-19,26-dinor-vitamin D analogs, and specifically 2-methylene-(20S,25S)-19,26-dinor-1α,25-dihydroxyvitamin D07-02-2009
20080312197PHARMACEUTICAL PRODUCTS CONTAINING HORMONES AND A 25-HYDROXY VITAMIN D COMPOUND - The present invention relates to pharmaceutical products containing progestins in combination with the 25 hydroxy Vitamin D compounds. The 25 hydroxy Vitamin D compounds are preferably administered with the progestins. In OC and HRT regimens, the 25 hydroxy Vitamin D compounds can be administered daily, or on a non-daily basis, and if so, preferably when the progestin dosages are the highest in the cycle.12-18-2008
20100144683METHODS FOR GENERATING MAMMALIAN MODELS OF ATOPIC DISEASES, AND SCREENING FOR THEIR TREATMENT - The present invention concerns a method for generating a human atopic disease-like phenotype, preferably an atopic dermatitis (AD)-like phenotype in a mammal comprising administering to said mammal at least one compound selected in the group comprising the physiologically active vitamin D3 (1α,25(OH)06-10-2010
20100144684Method of Safely and Effectively Treating and Preventing Secondary Hyperparathyroidism in Chronic Kidney Disease - A method of treating and preventing secondary hyperparathyroidism in CKD by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin Din a patient by administering 25-hydroxyvitamin D06-10-2010
20120196837METHOD OF TREATING FRAILTY - Disclosed is a method of treatment or prevention of frailty in an elderly patient, particularly having an age of 60 or older. The method provides the concomitant parenteral administration of a combination of an anabolic steroid and a vitamin D compound. A preferred combination comprises nandrolone decanoate and cholecalciferol (vitamin D08-02-2012
20090131378VITAMIN D DERIVATIVES ACTIVE ON THE VITAMIN D NUCLEAR RECEPTOR, PREPARATION AND USES THEREOF - The invention relates to vitamin D derivatives and their uses, particularly in the pharmaceutical industry. The invention discloses compounds having different interesting biological properties, including vitamin D nuclear receptor (VDR) agonist activity, as well as therapeutics methods by administering said compounds, in particular for treating cancer, psoriasis, autoimmune diseases, osteodistrophy and osteoporosis. It further relates to pharmaceutical compositions comprising said compounds and methods for preparing the same.05-21-2009
20090137536METHOD FOR TREATING AND PREVENTING HYPERPARATHYROIDISM - This invention relates to a method for treating or preventing hyperthyroidism associated with aging and/or with Aging-Related Vitamin D Deficiency (ARVDD) syndrome by administering a sufficient amount of an active vitamin D compound utilizing a variety of effective treatment protocols. The invention further relates to treating or preventing one or more of the following conditions, e.g., (1) primary vitamin D deficiency, (2) 1,25-(OH)05-28-2009
20080234238PHARMACEUTICAL PRODUCT CONTAINING PROGESTIN, GENISTEIN, AND VITAMIN D COMPOUND - A pharmaceutical product comprising multiple daily sequential dosages, said product comprising a progestin and genistein, and optionally a Vitamin D compound. Genistein is preferably at least 20 mg, and more preferably 50-80 mg. The progestin is selected from the group consisting of norgestimate in the range of 0.18-0.25 mg, levonorgestrel in the range of 0.05-0.3 mg, norgestrel in the range of 0.075-0.5 mg, norethindrone in the range of 0.5-1.0 mg, desogestrel in the range of 0.06-0.15 mg, gestodene in the range of 0.04-0.12 mg, dienogest in the range of 0.25-4.0 mg, drospirenone in the range of 0.25-4.0 mg, and medroxy-progesterone acetate in the range of 2.5-10 mg. The Vitamin D compound is preferably at a dosage of at least 400 IU.09-25-2008
20090325910COMPOSITIONS AND METHODS FOR TRANQUILIZING HEART MUSCLE - A pharmaceutical composition for tranquilizing cardiomyocytes present in heart muscle in a subject diagnosed with a cardiac overload disease comprises a therapeutically effective amount of a Vitamin D12-31-2009
20090099141COMPOSITIONS AND METHODS FOR TREATING VITAMIN D DEFICIENCIES - The present invention provides for: (a) an oral dosage of vitamin D3 for humans sufficient to maintain a serum level above a minimally sufficient level and below a toxic level when administered according to a schedule of at least one dosage a week up to at least one dosage a day, (b) methods for administering the oral dosages and (c) a kit involving a blister pack and a plurality of oral dosages with instructions for administering the dosages and a location on the blister pack for recording information related to the administration of each dosage, the name of the person receiving the dosages and additional relevant information.04-16-2009
20090105198NOVEL ESTROGENIC COMPOUNDS - Novel estrogenic compounds of Formula I are provided.04-23-2009
20080261925COMPOUNDS, COMPOSITIONS, KITS AND METHODS OF USE TO ORALLY AND TOPICALLY TREAT ACNE AND OTHER SKIN CONDITIONS BY ADMINISTERING A 19-NOR CONTAINING VITAMIN D ANALOG WITH OR WITHOUT A RETINOID - Oral and topical pharmaceutical compositions, kits and methods of treatment thereof for treating various skin disorder including acne, psoriasis, ichthyosis, photoaging, photodamaged skin, and, skin cancer. Exemplary vitamin D analogs as active pharmaceutical ingredients include 2-methylene-19-nor-20(S)-1α-hydroxy-bishomopregnacalciferol, 19-nor-26,27-dimethylene-20(S)-2-methylene-1α,25-dihydroxyvitamin D10-23-2008
20120077786METHODS AND COMPOSITIONS FOR DISEASE TREATMENT USING INHALATION - Methods and compositions for the treatment of pulmonary disease using inhalation are provided. In particular, the present disclosure provides novel methods and compositions for treating pulmonary diseases such as asthma, bronchitis, COPD, emphysema, lung cancer, pneumonia and pulmonary edema. In addition, the present disclosure provides novel methods and compositions for treating complications associated with pulmonary disease such as corticosteroid resistance and pulmonary tissue destruction. The compositions of the present disclosure comprise corticosteroid resistance agents including but not limited to vitamin D, calcitriol and equivalents thereof. The compositions of the present disclosure also comprise alveolar development and maintenance agents including but not limited to vitamin A, ATRA and equivalents thereof. The present invention provides effective administration of therapeutic agents to specific airways of the lungs by utilizing controlled site delivery.03-29-2012
20090209501METHOD OF TREATING AND PREVENTING SECONDARY HYPERPARATHYROIDISM - The a method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D08-20-2009
20100273748ANTIMICROBIAL THERAPY - Methods and compositions for modulating gene expression and the innate immune response by 1,25(OH)10-28-2010
201000162639, 10-SECOPREGNANE DERIVATIVE AND PHARMACEUTICAL - A main object of the invention is to provide a novel useful vitamin D01-21-2010
200902988001,25-DIHYDROXY, 20-CYCLOPROPYL,26-27-DEUTEROALKYL VITAMIN D3 COMPOUNDS AND METHODS OF USE THEREOF - The invention provides vitamin D12-03-2009
20100234329INGESTIBLE FILM COMPOSITION - The present invention relates to a novel ingestible film composition. More specifically, the invention is directed to a water-based, enzymatically-digested carboxymethylcellulose (CMC-Enz) film composition that is suitable for delivering pharmaceutical drugs, vitamins, natural products and other products to humans and animals. The invention further includes a method for manufacturing the novel composition. Advantageously, the film composition can accommodate an active ingredient in a quantity of up to approximately 60% of the overall weight of the final film.09-16-2010
20110130370Pharmaceutical composition comprising a strontium salt, vitamin D and A cyclodextrin - A pharmaceutical composition comprising a strontium salt, vitamin D and a cyclodextrin.06-02-2011
20110059927Calcium Formate For Use As A Dietary Supplement - A calcium formate composition for oral administration to an individual for the purpose of supplementary dietary calcium is disclosed.03-10-2011
20110059926Vitamin D Compounds and Methods for Reducing Ocular Hypertension (OHT) - The present invention relates to compounds and methods for reducing intraocular pressure and treating ocular hypertension in a subject.03-10-2011
20100227840USE OF 25-HYDROXY VITAMIN D3 TO IMPROVE MALE ANIMAL FERTILITY - The present invention relates to the use of 25-hydroxy vitamin D09-09-2010
20090075953DEUTERIUM-ENRICHED ED-71 - The present application describes deuterium-enriched ED-71, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.03-19-2009
20100137262Low Calcemic, Highly Antiproliferative, Analogs of Calcitriol - The disclosure provides compounds, compositions and methods using these compounds and compositions to stimulate the differentiation of cells and inhibit excessive cell proliferation of certain cells, including cancer cells and skin cells, which may be useful in the treatment of diseases characterized by abnormal cell proliferation and/or cell differentiation such as leukemia, myelofibrosis and psoriasis without the well known effect on calcium metabolism, which gives rise to hypercalcemia.06-03-2010
20130131023NEW POLYMORPHIC FORM OF A CALCIMIMETIC COMPOUND - The present invention relates to the crystalline, polymorphic Form C of the calcimimetic compound {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of characterization thereof by single crystal X-Ray crystallography (XRC), X-Ray Powder diffractometry, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Solid State NMR spectroscopy and Differential Scanning Calorimetry (DSC), and to its use. The invention also relates to the preparation of Form C by crystallization from a saturated solution of {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid in the presence of crystallization seeds of Form C, or alternatively by conversion of an amorphous starting material into the different crystalline polymorphic Form X by crystallization of {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, followed by a solid solution transformation thereof into the desired polymorphic Form C.05-23-2013
20110112056Use of Carbon-2-Modified-Vitamin D Analogs to Induce the Formation of New Bone - It has been discovered that the 2-carbon-modified derivatives of 1α,25-dihydroxyvitamin D05-12-2011
20110021470METHODS FOR TREATING CANCER COMPRISING THE ADMINISTRATION OF A VITAMIN D COMPOUND AND AN ADDITIONAL THERAPEUTIC AGENT, AND COMPOSITIONS CONTAINING THE SAME - Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a vitamin D compound in combination with at least one additional therapeutic agent, such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising vitamin D compounds and at least one additional therapeutic agent, such as an anti-cancer agent or a steroid, e.g., corticosteroid or more specifically, a glucocorticoid.01-27-2011
20110034426Method of Preventing Renal Disease and Treating Symptoms Thereof - The invention relates to novel methods of using 2-methylene-19-nor-20(S)-1,25-dihydroxyvitamin D02-10-2011
2009014334226,27-homologated-20-EPI-2-alkylidene-19-nor-vitamin D compounds - This invention provides a novel class of vitamin D related compounds, namely, the 2-alkylidene-19-nor-vitamin D derivatives, as well as a general method for their chemical synthesis. The compounds have the formula:06-04-2009
20110039809COMBINED USE OF 25-HYDROXY-VITAMIN D3 AND VITAMIN D3 FOR IMPROVING BONE MINERAL DENSITY AND FOR TREATING OSTEOPORISIS - We disclose the combined use of vitamin D (cholecalciferol) and 25-OH D3 (calcifediol) to treat and/or prevent osteoporosis. One or more bisphosphonate compounds to inhibit bone resorption may also be used. Forms and dosages of a pharmaceutical composition, as well as processes for manufacturing medicaments, are also disclosed.02-17-2011
20110124609Method of Preventing Type I Diabetes - The invention relates to novel methods of using 2α-methyl-19-nor-20(S)-1α,25-dihydroxyvitamin D05-26-2011
20110124608USE OF 25-HYDROXY VITAMIN D3 TO INCREASE MUSCLE MASS IN MAMMALS - Myogenesis in mammals can be promoted by a prenatal administration of 25-hydroxy vitamin D3 (25-OH D3). The 25-OH D3 can be administered to the pregnant mother, and the amount of muscle tissue in the offspring is increased relative to control mammals. Optimally, the 25-OH D3 supplements the diet continuously postnatally.05-26-2011
2011008212219-Nor-Vitamin D Analogs With 1,2- or 3,2-Cyclopentene Ring - 19-nor-vitamin D analogs having an additional cyclopentene ring connecting carbon 1 and carbon 2, or connecting carbon 3 and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro activities, making them therapeutic agents for the treatment or prophylaxis of some types of cancers, particularly leukemia, colon cancer, breast cancer, skin cancer or prostate cancer.04-07-2011
201100821236-Methylvitamin D3 Analogs and Their Uses - This invention discloses 6-methylvitamin D04-07-2011
20100022486COMPOUNDS - The present invention relates to substituted 3-Aminopyrazole compounds of formula (I):01-28-2010
20100179112Nutritional Intervention for Improving Muscular Function and Strength - The present invention provides a composition comprising HMB and Vitamin D. Methods of administering HMB and Vitamin D to an animal are also described. Vitamin D and HMB are administered to increase muscle mass, strength, and functionality. The combination of Vitamin D and HMB together has a synergistic effect, which results in a surprising and unexpected level of improvement in muscle mass, strength and functionality.07-15-2010
201301579871-DEOXY ANALOGS OF 1,25-DIHYDROXYVITAMIN D3 COMPOUNDS - This present disclosure is directed to novel prodrugs of activated vitamin D3 compounds. The prodrugs can be designed to have one or more beneficial properties, such as selective inhibition of the enzyme CYP24, low calcemic activity, and anti-proliferative activity. Specifically, these prodrugs are 1-deoxy prohormones of active Vitamin D analogs, e.g. analogs of calcitriol. This disclosure is also directed to pharmaceutical and diagnostic compositions containing the prodrugs of the invention, and to their medical use, particularly as prodrugs in the treatment and/or prevention of diseases.06-20-2013
20110086824(20S,22E)-2-Methylene-19-Nor-22-Ene-1Alpha,25-Dihydroxyvitamin D3 - This invention discloses (20S,22E)-2-methylene-19-nor-22-ene-1α,25-dihydroxyvitamin D04-14-2011
2008031891120-Cyclopropyl, 26,27-Alkyl/Haloalkyl Vitamin D3 Compounds and Methods of Use Thereof - The invention provides vitamin D12-25-2008
20090082317LOW-CALCEMIC 16,23-DIENE 25-OXIME ANALOGS OF 1ALPHA,25-DIHYDROXY VITAMIN D3 - The present invention provides novel 16,23-diene 25-oxime ether analogs of 1,25-dihydroxy vitamin D3, compositions comprising these compounds and methods of using these compounds as inhibitors of CYP24. In particular, the novel compound of the invention are useful for treating diseases which benefit from a modulation of the levels of 1,25-dihydroxy vitamin D3, for example, cell-proliferative disorders.03-26-2009
20080255072Composition for Inhibition of Cathepsin K - The present invention relates to the a method of inhibiting bone resorption in a mammal in need thereof with an oral pharmaceutical composition comprising a cathepsin K inhibitor, or a pharmaceutically acceptable salt thereof, or a mixture thereof, according to a continuous schedule having a dosage interval of once weekly, biweekly, twice monthly or once monthly.10-16-2008
20110257135TOPICAL PESTICIDE FORMULATION - Described are formulations and methods for animal pest control. A formulation for topical administration to animal pests includes a solution including an effective amount of cholecalciferol (also known as Vitamin D3) and at least one dermal penetrant or carrier, such that a lethal dose of the cholecalciferol can be delivered transdermally to an animal pest in solution, thereby being absorbed into the animal's bloodstream and subsequently causing the death of the animal. The formulation and method is effective at killing pests such as mice, rats, stoats, weasels, ferrets, rabbits, hedgehogs and possums.10-20-2011
20120309719(22E)-2-METHYLENE-26,27-CYCLO-22-DEHYDRO-1ALPHA-HYDROXY-19-NORVITAMIN D3 DERIVATIVES - Cyclopropane-containing vitamin D analogs of formulas I and IV are provided. Such compounds may be used in preparing pharmaceutical compositions and are useful in treating a variety of biological conditions.12-06-2012
2012014966922-Haloacetoxy-Homopregnacalciferol Analogs and Their Uses - This invention discloses 22-haloacetoxy-homopregnacalciferol analogs and specifically 22-bromoacetoxy-homopregnacalciferol and pharmaceutical uses therefor. This compound exhibits relatively little calcemic activity and does not promote cellular differentiation off HL-60 leukemia cells, but rather kills the cells. This cell death activity is found in small cell lung carcinoma also, but not in prostate cancer cells. This compound thus causes specific cell death in the absence of changes in calcium levels and without general toxicity in an animal. Therefore it might serve as a useful therapy for treatment of some forms of cancer, such as leukemia and lung cancer.06-14-2012
20090176749OIL-IN-WATER EMULSION LOTION CONTAINING 22-OXA-1ALPHA, 25-DIHYDROXYVITAMIN D3 AND METHOD OF TREATMENT OF SKIN DISORDER USING THE SAME - Provided is a lotion that exhibits high percutaneous absorption inherent in maxacalcitol, allows the maxacalcitol to be stable, and exhibits less dripping when it is applied to heads. A basic oil-in-water emulsion lotion containing 22-oxa-1α,25-dihydroxyvitamin D07-09-2009
20090176748METHODS AND COMPOSITIONS FOR CONTROLLED RELEASE ORAL DOSAGE OF A VITAMIN D COMPOUND - A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.07-09-2009
20080234239Topical composition - A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.09-25-2008
201100821211-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses - This invention discloses 1-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-1-desoxy-2-methylene-19-nor-vitamin D04-07-2011
20100197641FORMULATION FOR LIPOPHILIC AGENTS - The invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and processes for preparing and using the same.08-05-2010
20110118217Agonists for Antimicrobial Peptide Systems - Short chain fatty acids (SCFAs) and glycerol esters of SCFAs not previously used for that purpose are provided for use as a medicament for treating, preventing or counteracting microbial infections in animals, including humans, by stimulating the innate antimicrobial peptide defense system. Preferred compounds include phenyl substituted short chain fatty acids (SCFAs) derivatives and. Also provided are methods and compositions for treating, preventing or counteracting microbial infections, including bacterial, viral, fungal, and parasitic infections, by administration of medicaments comprising a secretagogue-effective amount of the compounds of the invention.05-19-2011
20130012483NOVEL PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NEURODEGENERATIVE OR NEUROVASCULAR DISEASES - The present invention relates to a pharmaceutical composition comprising an NMDA receptor antagonist and vitamin D as active ingredients for the treatment of neurodegenerative or neurovascular diseases.01-10-2013
20130012484PETROLEUM JELLY-FREE UNGUENT COMPOSITIONS COMPRISING VITAMIN D COMPOUNDS AND OPTIONALLY STEROIDAL ANTI-INFLAMMATORY AGENTS - Novel compositions in petroleum jelly-free unguent form, in particular for topical application, contain a vitamin D compound and optionally an active agent of the family of steroidal anti-inflammatory agents.01-10-2013
20110053898TOPICAL COMPOSITION COMPRISING VITAMIN D ANALOGUE AND CORTICOSTEROIDS - A topical pharmaceutical composition comprising therapeutically effective amounts of vitamin D or vitamin D analogues, corticosteroid and a straight chain C03-03-2011
20110306580PROPHYLACTIC AGENT OR THERAPEUTIC AGENT FOR DISEASE RESULTING FROM ABNORMAL BONE METABOLISM - The object of the present invention is to provide a therapeutic agent or a prophylactic agent for a disease resulting from an abnormal bone metabolism, especially osteoporosis which is more effective than conventional agents. Excellent therapeutic effect or prophylactic effect on a disease resulting from an abnormal bone metabolism, especially osteoporosis, compared with the effect in administration of each compound alone can be obtained by the combination of an N-hydroxybenzamidine derivative represented by Formula (I) or a salt thereof with an activated vitamin D or a prodrug thereof.12-15-2011
20110306579METHODS OF NEUROPROTECTION USING NEUROPROTECTIVE STEROIDS AND A VITAMIN D - Described herein are compositions and methods for treating or preventing nervous system injury. In particular, the methods and compositions relate to the use of at least one neuroprotective steroid, such as progesterone, and vitamin D.12-15-2011
20090209500USE OF VITAMIN D RECEPTOR AGONISTS AND PRECURSORS TO TREAT FIBROSIS - This application relates to methods of treating, preventing, and ameliorating fibrosis, such as fibrosis of the liver, kidney, or pancreas. In particular, the application relates to methods of using a vitamin D receptor agonist (such as vitamin D, vitamin D analogs, vitamin D precursors, and vitamin D receptor agonists precursors) for the treatment of fibrosis. Also disclosed are methods for screening for agents that treat, prevent, and ameliorate fibrosis.08-20-2009
20090111779METHODS OF USE FOR 2,5-DIHYDROXYBENZENE SULFONIC ACID COMPOUNDS FOR THE TREATMENT OF CANCER, ROSACEA AND PSORIASIS - The invention describes compositions and methods of use for 2,5-dihydroxybenzene sulfonic acid compounds and pharmaceutically acceptable salts thereof. The invention provides methods for (a) treating skin cancer; (b) treating cancer of the organs; (c) treating leukemia; (d) improving the efficacy of chemotherapy, radiation therapy and/or cancer immunotherapy; (e) treating rosacea; and (f) treating psoriasis by administration of a composition comprising at least one 2,5-dihydroxybenzene sulfonic acid compound or a pharmaceutically acceptable salt thereof, and, optionally at least one therapeutic agent. Also disclosed are compositions comprising administration of at least one 2,5-dihydroxybenzene sulfonic acid compound, or a pharmaceutically acceptable salt thereof, and, at least one therapeutic agent. In the invention the 2,5-dihydroxybenzene sulfonic acid compounds or pharmaceutically acceptable salts thereof are 2,5-dihydroxybenzene sulfonic acid, calcium 2,5-dihydroxybenzenesulfonate, potassium 2,5-dihydroxybenzenesulfonate, magnesium 2,5-dihydroxybenzenesulfonate and diethylamine 2,5-dihydroxybenzenesulfonate.04-30-2009
20090069276Treatment, prevention and amelioration of pulmonary disorders associated with chemotherapy or radiotherapy with active vitamin D compounds or mimics thereof - The present invention relates to a method for preventing, treating or ameliorating pulmonary disorders in a patient receiving a chemotherapeutic or radiotherapeutic agent or treatment comprising administering to the patient a pharmaceutical composition comprising an effective amount of active vitamin D compound or a mimic thereof. According to the invention, the active vitamin D compound, or the mimic thereof, may be administered by HDPA so that high doses of the active vitamin D compound can be administered to an animal without inducing severe symptomatic hypercalcemia.03-12-2009
20100063013CATHEPSIN CYSTEINE PROTEASE INHIBITORS - The present invention relates to novel compounds of the formula (I), wherein R′-R7, X, Y, D and n are as defined in the specification. These compounds are cysteine protease inhibitors which include but are not limited to inhibitors of cathepsms K, L, S and B and are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.03-11-2010
20120046252Calcium Formate for Use as a Dietary Supplement - A calcium formate composition for oral administration to an individual for the purpose of supplementary dietary calcium is disclosed.02-23-2012
20120004200TOPICAL PHARMACEUTICAL COMPOSITION CONTAINING A WATER-SENSITIVE ACTIVE PRINCIPLE - A topical pharmaceutical composition including, as a pharmaceutical active agent, a water-sensitive compound in a solubilised form in a physiologically acceptable medium is described. A method for preparing such a composition, and uses thereof in dermatology are also described.01-05-2012
20120046253STABLE PHARMACOLOGICALLY ACTIVE COMPOSITIONS INCLUDING VITAMIN D CONTAINING AND CORTICOSTEROID COMPOUNDS WITH LOW pH COMPATIBILITY - Provided are pharmaceutical compositions comprising at least one vitamin D-containing compound, at least one corticosteroid compound, and at least one solvent component selected from the group consisting of triglycerides, sorbitan, sorbitan fatty esters, cetearyl glucoside, PEG-n sorbitan stearate, acrylamide/sodium acryloyldimethyl taurate copolymers, and mixtures thereof. Also provided are methods of making such compositions, and methods for treating psoriasis using such compositions.02-23-2012
20080261926Pharmaceutical Calcimimetics - This invention relates to novel calcimimetic compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by binding to, and modulating the sensitivity of, calcium receptors on the parathyroid gland.10-23-2008
20110166111COMPOSITION FOR THE REDUCTION OF DRIP LOSSES IN PORK - 25-hydroxyvitamin D3 has been found to reduce drip losses in swine carcasses. Feed containing about 25-75 μg/kg 25-hydroxyvitamin D3 improves the water holding capacity of meats, including pork.07-07-2011
20120015916Method for Treating Secondary Hyperparathyroidism in CKD - A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.01-19-2012
20120015915FORMULATIONS OF 14-EPI-ANALOGUES OF VITAMIN D - The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.01-19-2012
20120015914FORMULATIONS OF 14-EPI-ANALOGUES OF VITAMIN D - The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.01-19-2012
20120015913Formulations of 14-EPI-Analogues of Vitamin D - The present invention provides new formulations of 14-epi-analogues of vitamin D, such as inecalcitol, providing improved absorption profile.01-19-2012
20120115824Vitamin D Receptor Agonists and Uses Thereof - Disclosed is a compound of Formula (I)05-10-2012
20120028933Cell Culture Media Supplement and Method of Molecular Stress Control - A novel class of agents has been identified to serve as cell-guard agents and/or target-specific supplements to increase cell quality and yield, as well as select for target cell populations. Laboratory experiments have demonstrated the use of cell-guard agents and/or target-specific supplements in the bioprocessing of cells as well as in selecting out a desired cell population. Several potential additive agents (both natural and synthetic) have been identified during these studies, including Vitamin D02-02-2012
20120058977PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS - A pharmaceutical composition for the treatment of a disease caused by a bacterium that belongs to the group of nocardioform actinomycetes, said composition comprising an effective amount of a compound selected from compound I, (+)-compound II, (−)-compound II, compound III, or mixtures thereof.03-08-2012
20090163452COMPOSITIONS AND METHODS FOR LOWERING SERUM CHOLESTEROL - The invention provides a method for lowering circulating LDL-cholesterol or total cholesterol in a human in need thereof, comprising: orally administering to the human a therapeutically effective amount of a statin and vitamin D daily for at least about 6 weeks, wherein the vitamin D is administered by one or more pharmaceutical compositions.06-25-2009
201201574182-Methylene-19-Nor-Vitamin D Analogs and Their Uses - This invention discloses 2-methylene-19-nor-vitamin D analogs, and specifically (20S)-25-hydroxy-2-methylene-19-nor-vitamin D06-21-2012
20110092468Pharmaceutical Calcimimetics - This invention relates to novel calcimimetic compounds, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by binding to, and modulating the sensitivity of, calcium receptors on the parathyroid gland.04-21-2011
20110105444ONCE-A-WEEK ADMINISTRATION OF 25-HYDROXY VITAMIN D3 TO SUSTAIN ELEVATED STEADY-STATE PHARMACOKINETIC BLOOD CONCENTRATION - An oral dosage form comprising a single dose of 25-hydroxy-vitamin D05-05-2011
20100093676POLYAPHRON TOPICAL COMPOSITION WITH VITAMIN D - A topical composition comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion and at least one vitamin D or vitamin D analogue.04-15-2010
20100093678Compositions and methods of the treatment of obesity and osteoporosis - The present invention relates to naturally occurring compositions comprising vitamin D3 or related analog and methods for treating obesity and/or osteoporosis and reducing body fat or enhancing a bone graft in patients in need thereof.04-15-2010
20100093677METHOD OF INDUCING NEGATIVE CHEMOTAXIS - The current invention is directed to methods of inducing the negative chemotaxis of a migratory cell comprising contacting the cell with a compound selected from the group consisting of idebenone, benazepril, rolipram, moxonidine, lamivudine, loxoprofen, terbinafine, Synephrine, 6-aminoindazole, and a Vitamin D analog, or a pharmaceutically acceptable salt of any of thereof.04-15-2010
20100093674Skin cancer prevention method and product - The increased use of sunscreens, while limiting damage to the DNA, may promote cancer growth by preventing vitamin D synthesis in the skin. According to the present invention, the beneficial effects of UV radiation are obtained by incorporating vitamin D into the topical after-sun lotions and creams, applied to the skin after exposure to the sun to prevent its harmful effects. Application of the after-sun product provides vitamin D, which is activated by the skin to calcitriol for cancer prevention. Because calcitriol also promotes cellular growth and differentiation, the topical after-sun product with vitamin D may be of benefit for photoaging.04-15-2010
20100093675NOVEL METHOD - There is provided a method of prevention of adhesions, eg surgical adhesions, which comprises using a vitamin D compound.04-15-2010
20090298801Petroleum jelly-free unguent compositions comprising vitamin D compounds and optionally steroidal anti-inflammatory agents - Novel compositions in petroleum jelly-free unguent form, in particular for topical application, contain a vitamin D compound and optionally an active agent of the family of steroidal anti-inflammatory agents.12-03-2009
20090131379VITAMIN D RECEPTOR ACTIVATORS AND METHODS OF MAKING - The invention relates to compounds that are vitamin D receptor activators, compositions comprising such compounds, methods of using such compounds and compositions, processes for preparing such compounds, and intermediates obtained during such processes.05-21-2009
20120214773FORMULATION FOR LIPOPHILIC AGENTS - The invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and processes for preparing and using the same.08-23-2012
20120165301BENZODIAZEPINE COMPOSITIONS FOR TREATING EPIDERMAL HYPERPLASIA AND RELATED DISORDERS - The present invention provides, for example, pharmaceutical compositions comprising a benzodiazepine compound and an agent selected from the group consisting of a topical steroid, a keratolytic agent, a topical retinoid, a coal tar, and a vitamin D-3 analog. The pharmaceutical compositions are useful for treating medical disorders, such as epidermal hyperplasia.06-28-2012
20120258938Enzymatic Production or Chemical Synthesis and Uses for 5,7-Dienes and UVB Conversion Products Thereof - Provided herein are steroidal compounds that are androsta-5,7-dienes or pregna-5,7-dienes and ultraviolet B (UVB) conversion products thereof and cholecalciferol derivatives hydroxylated at one or more of C1, C17, C20, C23, C24, C25, and C26 which includes pharmaceutical, cosmeceutical or nutraceutical compositions of the steroidal compounds as shown in Tables 1A, 2A and 3. Also provided is a method for producing hydroxylated metabolites of cholecalciferol via CYP11A1, CYP24, CYP27A1, or CYP27B1 enzyme systems where the hydroxylase has an activity to hydroxylate position C1 or C20 or other position of the sidechain of a secosteroid or its 5,7-dieneal precursor and the hydroxylated metabolites so produced. Methods are provided for inhibiting proliferation of either a normally or abnormally proliferating cell, for modifying immune activity, or for treating a condition associated with the proliferating or quiescent cell or immune cells by contacting the cell with or administering any of the compounds described herein.10-11-2012
201000099472-Methylene-19,26-Dinor-(20S,22E,25R)-Vitamin D Analogs - This invention discloses 2-methylene-19,26-dinor-(20S,22E,25R)-vitamin D analogs, and specifically 2-methylene-19,26-dinor-(20S,22E,25R)-1α,25-dihydroxyvitamin D01-14-2010
201000099462-Methylene-19,26-Dinor-(20R,22E,25R)-Vitamin D Analogs - This invention discloses 2-methylene-19,26-dinor-(20R,22E,25R)-vitamin D analogs, and specifically 2-methylene-19,26-dinor-(20R,22E,25R)-1α,25-dihydroxyvitamin D01-14-2010
2010000994519-NOR-VITAMIN D ANALOGS WITH 3,2-DIHYDROFURAN RING - 19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 3β-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, metabolic bone diseases, osteomalacia, osteopenia, secondary hyperparathyroidism, psoriasis, or other skin diseases.01-14-2010
201000099422-Methylene-(17Z)-17(20)-Dehydro-19,21-Dinor-Vitamin D Analogs - This invention discloses 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-vitamin D analogs, and specifically 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-1α, 25-dihydroxyvitamin D01-14-2010
201000099412-Methylene-20(21)-Dehydro-19-Nor-Vitamin D Analogs - This invention discloses 2-methylene-20(21)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19-nor-1α,25-dihydroxyvitamin D01-14-2010
201000099402-Methylene-(20E)-20(22)-Dehydro-19-Nor-Vitamin D Analogs - This invention discloses 2-methylene-(20E)-20(22)-dehydro-19-nor-vitamin D analogs, and specifically 2-methylene-(20E)-20(22)-dehydro-19-nor-1α,25-dihydroxyvitamin D01-14-2010
2010000994419-Nor-Vitamin D Analogs with 1,2-Dihydrofuran Ring - 19-nor-vitamin D analogs having an additional dihydrofuran ring connecting the 1α-oxygen and carbon-2 of the A-ring of the analog, and pharmaceutical uses therefore, are described. These compounds exhibit selective in vitro and in vivo activities, making them therapeutic agents for the treatment or prophylaxis of autoimmune diseases, some types of cancers, secondary hyperparathyroidism, psoriasis, or other skin diseases.01-14-2010
20100009948Combined calcium, magnesium and vitamin D supplements - The present invention relates to oral nutritional and therapeutic products which are useful for providing vitamins and minerals required for bone health. The present invention is an oral nutritional and therapeutic composition of calcium succinate, magnesium R-(+)-alpha-lipoate, and Vitamin D for use in the maintenance of bone health, the optimization of bone growth, reducing the risk of bone fracture, and the prevention and treatment of osteoporosis. The pharmaceutical products and methods of the present invention are particularly useful in building bone mass, quality, and density during growth, maintaining bone mass, quality, and density over time, reducing bone fracture risk, and treating osteoporosis in men and women.01-14-2010
20100286101PHARMACEUTICAL COMPOSITION INCLUDING A CORTICOSTEROID AND A VITAMIN D ANALOG HAVING IMPROVED STABILITY - A composition that includes a corticosteroid (e.g., betamethasone dipropionate), a vitamin D analog (e.g., calcipotriene) and an acyl ester of 1,2,3-trihydroxypropane or an ether thereof; and a method of treating a dermatologic condition (e.g., psoriasis vulgaris) in a mammal (e.g., human); are provided. The method includes topically administering to a mammal in need of such treatment an effective amount of the composition, to the affected topical area, for a period of time effective to treat the dermatologic condition.11-11-2010
20120190656METHODS FOR SELECTING THERAPIES TO IMPROVE HDL CHOLESTEROL AND TRIGLYCERIDE LEVELS - Disclosed herein are diagnostic methods for determining whether subjects will be responsive to vitamin D therapy. The methods involve the detection of one or more single nucleotide polymorphisms in a test sample, in combination with other clinical factors. The tests are suitable for diagnosing and determining a treatment regime for patients having or suspected of having a cardiovascular disease, including hyperlipidemia or hypertriglyceridemia.07-26-2012
20080300223(20R)-2a-Methyl-19,26,27-Trinor-Vitamin D Analogs - This invention discloses (20R)-2α-methyl-19,26,27-trinor-vitamin D analogs, and specifically (20R)-2α-methyl-19,26,27-trinor-1α,25-dihydroxyvitamin D12-04-2008
20100204189Methods and Compounds for Vitamin D Therapy - Methods and compositions comprising 1,25-dihydroxyvitamin D08-12-2010
20080280860Use of Vitamin D Compounds to Treat Endometriosis - The use of vitamin D compounds in the treatment or prevention of endometriosis, methods for the treatment or prevention of endometriosis by administering a vitamin D compound, and compounds for use therein.11-13-2008
20120322776CUTANEOUS COMPOSITION COMPRISING VITAMIN D ANALOGUE AND A MIXTURE OF SOLVENT AND SURFACTANTS - A pharmaceutical composition comprising a vitamin D derivative or analogue as the active ingredient dissolved in a three-component surfactant-solvent mixture is useful in the treatment of dermal disorders or conditions.12-20-2012
201203227753-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses - This invention discloses 3-desoxy-2-methylene-19-nor-vitamin D analogs, and specifically (20S)-3-desoxy-2-methylene-1α,25-dihydroxy-19-nor-vitamin D12-20-2012
20120322774CHOCOLATE HAVING CHOLECALCIFEROL AND METHOD FOR FORMING - A method for forming chocolate having cholecalciferol is provided. The method includes mixing cholecalciferol into an oil to produce a cholecalciferol-oil mixture. The temperature of a chocolate base is raised to a melting point, and the cholecalciferol-oil mixture is blended into the chocolate base to form a cholecalciferol-chocolate.12-20-2012
20110237557DIASTEREOMERS OF 2-METHYLENE-19-NOR-22-METHYL-1ALPHA,25-DIHYDROXYVITAMIN D3 - Compounds of formula I are provided where X09-29-2011
20110237556(20S)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-DIHYDROXYVITAMIN D3 AND (20R)-2-METHYLENE-19-NOR-22-DIMETHYL-1alpha,25-HYDROXYVITAMIN D3 - Compounds of formula I are provided where X09-29-2011
20100234330Novel Estrogenic Compounds - Novel estrogenic compounds of Formula I are provided.09-16-2010
20120329764METHODS AND COMPOSITIONS FOR THE TREATMENT OF MIGRAINE HEADACHES - The present invention is related to compositions and methods for treating or reducing the likelihood of a migraine, reducing the severity of migraine, reducing the frequency of migraines, reducing the duration of migraine, and ameliorating the symptoms of a migraine. The methods and compositions of the present invention may also be used to treat or prevent condition characterized by increased cardiovascular risk or endothelial dysfunction and musculoskeletal symptoms.12-27-2012
20100160267Treatment of Inflammatory Bowel Disease With 2-Methylene-19-Nor-Vitamin D Compounds - A method of preventing and/or treating inflammatory bowel disease, particularly ulcerative colitis and Crohn's disease, is disclosed. The method involves administering a 2-methylene-19-nor-vitamin D compound in an amount effective to treat the disease. The administration of a 2-methylene-19-nor-vitamin D compound also prevents the development of or delays the onset of inflammatory bowel disease in susceptible individuals. The preferred compounds are 1α-hydroxy-2-methylene-19-nor-homopregnacalciferol and 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D06-24-2010
201001304549,10-SECOPREGNANE DERIVATIVES AND MEDICINE - A novel useful vitamin D3 derivative which is reduced in influence on systemic calcium metabolism while retaining excellent vitamin D3 activity. The derivative is a 9,10-secopregnane derivative represented by the following general formula [1]. Also provided is a medicinal composition containing the derivative as an active ingredient. In the general formula [1], Y represents (1) a single bond, (2) alkylene (3) alkenylene, or (4) phenylene; R05-27-2010
201300180212Alpha-Methyl and 2Beta-Methyl Analogs of 19,26,27-Trinor-(20S)-1Alpha-Hydroxyvitamin D3 and Their Uses - This invention discloses 2α-methyl and 2β-methyl analogs of 19,26,27-trinor-(20S)-1α-hydroxyvitamin D01-17-2013
20130023501PHARMACEUTICAL COMPOSITION COMPRISING SOLVENT MIXTURE AND A VITAMIN D DERIVATIVE OR ANALOGUE - A substantially anhydrous, topical pharmaceutical composition comprising a non-alcoholic three-component solvent mixture and a biologically active vitamin D derivative or analogue dissolved therein as well as a pharmaceutically acceptable carrier may be used in the treatment of dermal conditions.01-24-2013
20080249074Composition for the Transdermal Administration of Physiologically Active Agents - Improved composition for the administration of a physiologically active agent through the skin which comprises at least one vegetable oil, oleic acid, and at least one lactone of a saturated or unsaturated fatty acid of 5 to 22 carbon atoms, said two last components acting as absorption enhancers. Using said composition, unexpected increased values of the absorption of the physiologic active agent through the skin are obtained due to an unpredictable synergistic effect.10-09-2008
20080227759Topical composition - A composition suitable for topical application comprising a continuous phase and at least one discontinuous phase, said composition comprising at least one polyaphron dispersion, at least one vitamin D or vitamin D analogue and at least one corticosteroid.09-18-2008
20130143845VITAMIN D COMPOUNDS AND METHODS FOR ENHANCING MUSCLE STRENGTH, AND PREVENTION AND TREATMENT OF DISEASE IN HUMAN BEINGS - Compositions and methods for enhancing muscular strength through the development of fast twitch skeletal muscle fibers comprising the steps of administering therapeutically effective amounts of Vitamin D, folic acid, calcium carbonate and potassium gluconate compounds to a subject, and the treatment and prevention of disease in human beings.06-06-2013
201301025732-METHYLENE-VITAMIN D ANALOGS AND THEIR USES - This invention discloses 2-methylene-vitamin D analogs, and specifically (20S)-25-hydroxy-2-methylene-vitamin D04-25-2013
201301025742-METHYLENE-VITAMIN D ANALOGS AND THEIR USES - This invention discloses 2-methylene-vitamin D analogs, and specifically (20S)-1α,25-dihydroxy-2-methylene-vitamin D04-25-2013
20130131022Methods for Controlled Release Oral Dosage of a Vitamin D Compound - A stable, controlled release formulation for oral dosing of vitamin D compounds is disclosed. The formulation is prepared by incorporating one or more vitamin D compounds into a solid or semi-solid mixture of waxy materials. Oral dosage forms can be prepared by melt-blending the components described herein and filling gelatin capsules with the formulation.05-23-2013
201301784492-Methylene-20(21)-Dehydro-19,24,25,26,27-Pentanor-Vitamin D Analogs - This invention discloses 2-methylene-20(21)-dehydro-19,24,25,26,27-pentanor-vitamin D analogs, and specifically 2-methylene-20(21)-dehydro-19,24,25,26,27-pentanor-1α-hydroxyvitamin D07-11-2013
20130178450METHODS FOR INCREASING THE PRODUCTION OR ACTIVITY OF CATALASE - Methods and compositions for increasing the production or activity of catalase in an animal are disclosed. The methods comprise administering vitamin D to the animal in an amount effective to increase catalase production or activity. Methods for treating catalase deficiency, extending the prime years of an animal's life, promoting health and wellness of an animal, and improving the quality of life for an animal through the vitamin D-mediated increase in catalase production or activity are also disclosed. Methods of screening for vitamin D mimetics based on their ability to increase the production or activity of catalase in cells in a manner similar to vitamin D are also disclosed.07-11-2013
20130143846POLYMORPHIC FORM OF A CALCIMIMETIC COMPOUND - The present invention relates to the crystalline, polymorphic Form X of the calcimimetic compound {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid, to methods of preparation thereof, to methods of characterization thereof by single crystal X-Ray crystallography (XRC), X-Ray Powder diffractometry, attenuated total reflectance Fourier transform infrared (ATR-FTIR) spectroscopy, Solid State NMR spectroscopy and Differential Scanning Calorimetry (DSC), and to its use. The invention also relates to the preparation of Form X by crystallization from a saturated solution of {4-[(1R,3S)-3-((R)-1-Naphthalen-1-yl-ethylamino)-cyclopentyl]-phenoxy}-acetic acid in a C06-06-2013
20130137662USE OF CANTHAXANTHIN AND/OR 25-OH D3 FOR IMPROVED REPRODUCTIVITY AND PERFORMANCE OF ROOSTERS - The present invention relates to the use canthaxanthin and/or 25-hydroxy vitamin D3 (25-OH D3) for improving reproductive performance of roosters. More particularly, the invention relates to the use of Canthaxanthin and/or 25-hydroxy canthaxanthin in the manufacture of a food or veterinary composition for improving reproductive performance of roosters.05-30-2013
20110312923FORMULAS COMPRISING HIGHLY SOLUBLE ELEMENTS AND VITAMIN FOR THE PREVENTION AND AMELIORATION OF OSTEOPOROSIS - The present invention provides formulas of elemental compositions encompassing acetate salts of calcium, magnesium and zinc along with vitamin D12-22-2011
201202832282alpha-Methyl and 2beta-Methyl Analogs of 19,26-Dinor-1alpha,25-Dihydroxyvitamin D3 and Their Uses - This invention discloses 2α-methyl and 2β-methyl analogs of 19,26-dinor-1α,25-dihydroxyvitamin D11-08-2012
20120283227(20S)-24-(p-Toluenesulfonyloxy)-25,26,27-Trinorvitamin D3 Analogs and Their Uses - This invention discloses (20S)-24(p-toluenesulfonyloxy)-25,26,27-trinorvitamin D11-08-2012
20120028934STABLE PHARMACOLOGICALLY ACTIVE COMPOSITIONS INCLUDING VITAMIN D-CONTAINING AND CORTICOSTEROID COMPOUNDS WITH LOW pH COMPATIBILITY - Provided are pharmaceutical compositions comprising at least one vitamin D-containing compound, at least one corticosteroid compound, and at least one solvent component selected from the group consisting of triglycerides, sorbitan, sorbitan fatty esters, cetearyl glucoside, PEG-n sorbitan stearate, acrylamide/sodium acryloyldimethyl taurate copolymers, and mixtures thereof. Also provided are methods of making such compositions, and methods for treating psoriasis using such compositions.02-02-2012
20130196958METHODS OF NOURISHING ANIMALS - The present invention relates to methods of maintaining, and methods of restoring, a desired calcium homeostasis in a non-human terrestrial animal by administering an effective amount of one or more Calcium-Sensing Receptor modulators (CaSRs) to the animal. The invention further provides methods of reducing foot lesions in chickens. The invention also relates to food compositions useful in the methods of the invention.08-01-2013
20130210779METHOD OF IDENTIFYING TRIPLE NEGATIVE BREAST CANCER - The present invention provides means for identifying or classifying breast tumors based on the levels of nuclear cathepsin-L (CTSL) and nuclear p53 binding protein (53BP1), and methods of treating thereof.08-15-2013
20130210780Nutritional Composition for the Stimulation of Muscle Protein Synthesis - The invention relates to the use of an anabolic amino acid derivative stimulus acting in combination with vitamin D for the manufacture of a medicament or nutritional composition for the prevention and/or treatment of a loss of any one of muscle mass, muscle strength, muscle function, and physical function, or any combination thereof, in a mammal.08-15-2013
2013021078123-YNE-VITAMIN D3 DERIVATIVE - To provide a novel vitamin D08-15-2013

Patent applications in class 9,10-seco- cyclopentanohydrophenanthrene ring system (e.g., vitamin D, etc.) DOAI

Patent applications in all subclasses 9,10-seco- cyclopentanohydrophenanthrene ring system (e.g., vitamin D, etc.) DOAI